These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 160589)

  • 101. Inhibition of platelet-surface-bound proteins during coagulation under flow II: Antithrombin and heparin.
    Miyazawa K; Fogelson AL; Leiderman K
    Biophys J; 2023 Jan; 122(1):230-240. PubMed ID: 36325617
    [TBL] [Abstract][Full Text] [Related]  

  • 102. The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.
    Ceriello A; Quatraro A; Marchi E; Barbanti M; Dello Russo P; Lefebvre P; Giugliano D
    Diabet Med; 1990 May; 7(4):343-8. PubMed ID: 2140088
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin.
    Tsiang M; Jain AK; Gibbs CS
    J Biol Chem; 1997 May; 272(18):12024-9. PubMed ID: 9115268
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Procoagulant and fibrinolytic activity after polytrauma in rat.
    Wu X; Darlington DN; Cap AP
    Am J Physiol Regul Integr Comp Physiol; 2016 Feb; 310(4):R323-9. PubMed ID: 26632604
    [TBL] [Abstract][Full Text] [Related]  

  • 105. The anticoagulant mechanism of action of heparin in contact-activated plasma: inhibition of factor X activation.
    McNeely TB; Griffith MJ
    Blood; 1985 May; 65(5):1226-31. PubMed ID: 3995171
    [TBL] [Abstract][Full Text] [Related]  

  • 106. The inhibition of human plasmin by human antithrombin-heparin cofactor.
    Highsmith RF; Rosenberg RD
    J Biol Chem; 1974 Jul; 249(14):4335-8. PubMed ID: 4276455
    [No Abstract]   [Full Text] [Related]  

  • 107. Factors influencing the acceleration of human factor XIa inactivation by antithrombin III.
    Scott CF; Colman RW
    Blood; 1989 May; 73(7):1873-9. PubMed ID: 2785417
    [TBL] [Abstract][Full Text] [Related]  

  • 108. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Thromb Res; 1985 Oct; 40(2):135-46. PubMed ID: 3878009
    [TBL] [Abstract][Full Text] [Related]  

  • 109. The molecular-mass dependence of dextran sulfate enhancement of inactivation of thrombin and fibrinogen and on factor Xa neutralization by antithrombin III.
    Oshima G
    Biol Chem Hoppe Seyler; 1989 Jul; 370(7):715-21. PubMed ID: 2476159
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells.
    Hedin U; Frebelius S; Sanchez J; Dryjski M; Swedenborg J
    Arterioscler Thromb; 1994 Feb; 14(2):254-60. PubMed ID: 8305417
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Thrombin-antithrombin III and plasmin-antiplasmin complexes as indicators of in vivo activation of the coagulation and/or fibrinolytic systems.
    Collen D
    Acta Clin Belg; 1977; 32(6):398-402. PubMed ID: 151470
    [No Abstract]   [Full Text] [Related]  

  • 112. Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions.
    Walenga JM; Bara L; Samama MM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):100-7. PubMed ID: 4035361
    [No Abstract]   [Full Text] [Related]  

  • 113. Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III.
    Gan ZR; Li Y; Chen Z; Lewis SD; Shafer JA
    J Biol Chem; 1994 Jan; 269(2):1301-5. PubMed ID: 8288594
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Two-substrate reaction model for the heparin-catalyzed bovine antithrombin/protease reaction.
    Pletcher CH; Nelsestuen GL
    J Biol Chem; 1983 Jan; 258(2):1086-91. PubMed ID: 6822493
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin.
    Olson ST; Shore JD
    J Biol Chem; 1982 Dec; 257(24):14891-5. PubMed ID: 7174671
    [No Abstract]   [Full Text] [Related]  

  • 116. Coagulant and noncoagulant thrombin enzymatic activity on the endothelium.
    Frebelius S; Nydahl S; Swedenborg J
    Blood Coagul Fibrinolysis; 1990 Aug; 1(3):285-92. PubMed ID: 2103313
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Inactivation of thrombin in heparin-PVA coated tubes.
    Rollason G; Sefton MV
    J Biomater Sci Polym Ed; 1989; 1(1):31-41. PubMed ID: 2488845
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. The reaction step limiting heparin turnover in thrombin neutralization.
    Olson ST; Shore JD
    J Biol Chem; 1986 Oct; 261(28):13151-9. PubMed ID: 3759953
    [TBL] [Abstract][Full Text] [Related]  

  • 119. The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay.
    Malikova I; Husakova M; Bilkova J; Brzezkova R; Hrachovinova I; Kvasnicka T
    Clin Lab; 2023 Oct; 69(10):. PubMed ID: 37844053
    [TBL] [Abstract][Full Text] [Related]  

  • 120. [Effects of low molecular weight heparin (FR-860) on coagulative and fibrinolytic activities].
    Hamano S; Kinukawa M; Komatsu H; Ikeda S; Sakuragawa N
    Nihon Yakurigaku Zasshi; 1989 Oct; 94(4):243-9. PubMed ID: 2613105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.